Core Insights - Abbott has launched Libre Assist, a new feature within the Libre app aimed at helping individuals with diabetes make informed food choices by predicting glucose impacts before meals [1][6][8] - The feature utilizes a color-coded rating system to indicate the potential glucose impact of foods, enhancing decision-making for users [2][7] - Libre Assist integrates generative AI to provide personalized meal guidance and confirms glucose effects using data from Abbott's continuous glucose monitoring (CGM) systems [4][6][8] Product Features - Libre Assist offers in-the-moment meal guidance by allowing users to input food data through photos or text descriptions, predicting glucose impact with a color-coded system: green for minor, yellow for moderate, and orange for major [7] - After meals, the app provides personalized feedback based on actual glucose data from the Libre CGM systems, helping users understand their unique responses to different foods [7][8] - The feature is available at no additional cost within the Libre app, requiring no separate subscription or prescription [8][9] Market Context - Abbott's FreeStyle Libre technology has been a leader in diabetes care for over a decade, currently used by more than 7 million people in over 60 countries [9] - The launch of Libre Assist is positioned as a significant advancement in diabetes management, addressing the need for more proactive tools beyond traditional food logging apps [2][8]

Group 1 - As of January 2, 2026, two stocks in the health care sector are identified as potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] - Teva Pharmaceutical Industries Ltd has an RSI value of 71.6, with a recent stock price of $31.21, reflecting a 16% gain over the past month [6] - Exact Sciences Corp has an RSI value of 77.8, with a recent stock price of $101.56, reflecting a 7% gain over the past month [6] Group 2 - Teva's long-term issuer credit rating was upgraded to 'BB+' from 'BB' by S&P Global Ratings, with a stable outlook [6] - Abbott Laboratories agreed to acquire Exact Sciences for $105 per common share, totaling approximately $21 billion in equity value [6] - Exact Sciences has an estimated enterprise value of $23 billion following the acquisition announcement [6]

Core Viewpoint - Julie & Holleman LLP is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp, raising concerns about the fairness of the $105 per share deal price, which may be undervalued compared to potential estimates of $136.25 per share [1][2][3] Group 1: Acquisition Details - The acquisition deal was announced in November 2025 and is expected to close in the second quarter of 2026 [2] - Exact Sciences filed a preliminary proxy statement with the SEC on December 29, 2025, indicating that no other bidders were considered during the acquisition process [2] Group 2: Legal Investigation - Julie & Holleman LLP is investigating potential claims regarding the apparent unfairness of the deal and possible conflicts of interest [3] - The firm has a history of securing hundreds of millions of dollars for clients in similar cases, indicating their experience in shareholder litigation [3][4]

Core Viewpoint - The chronic pain medical device market in China is expected to grow significantly, driven by factors such as an aging population, increasing prevalence of chronic diseases, improved policy and insurance environments, and technological advancements [5][11]. Market Overview - The sales revenue of China's chronic pain medical device market is projected to reach $386.51 million in 2024 and $720 million by 2031, with a compound annual growth rate (CAGR) of 9.29% from 2025 to 2031 [5]. Industry Concentration and Competition - Major players in the Chinese market include Medtronic, Xiangyu Medical, Boston Scientific, Abbott, and OMRON, with the top three companies holding approximately 55.9% of the market share in 2024 [9]. Development Drivers - The market is primarily driven by three factors: 1. Aging population and high incidence of chronic diseases, leading to increased demand for pain management devices [11]. 2. Improved policies and insurance frameworks that facilitate multi-disciplinary management of pain [11]. 3. Technological advancements, including wearable devices and smart pain management solutions, enhancing personalized treatment options [11]. Challenges - The industry faces several challenges: 1. Fragmented market competition, with international brands dominating high-end segments while domestic companies focus on mid to low-end markets [11]. 2. High regulatory and clinical entry barriers, increasing pressure on small and medium enterprises [11]. 3. Incomplete payment systems, limiting the adoption of certain pain management devices in primary care and home settings [11]. 4. Insufficient awareness among patients and doctors regarding non-drug pain treatments, necessitating further market education [11]. Future Trends - The market is expected to trend towards smart and home-based solutions, with advancements in AI, big data, and IoT enabling remote monitoring and personalized treatment [12]. - The demand for portable and easy-to-use devices is rising, shifting the market focus from hospital-centric to a dual "hospital + home" model [12]. - Domestic innovation and international expansion are anticipated to be key trends, with policies supporting local manufacturers and new market opportunities emerging in regions like Southeast Asia and the Middle East [12]. Policy Framework - The Chinese government emphasizes the development of the medical device sector through various policies aimed at enhancing innovation and competitiveness [13][15]. - Key policies include the "Healthy China 2030" initiative and the "Made in China 2025" plan, which focus on improving the innovation capabilities of medical devices [13][15]. Supply Chain Analysis - The supply chain for chronic pain medical devices includes upstream raw material suppliers such as Nippon Steel and SABIC, and downstream markets comprising hospitals, home care, and rehabilitation centers [19][20]. - The hospital sector is the primary market for high-end devices, while the home care segment is rapidly growing, particularly for non-invasive devices like TENS units [20].

Industry Overview - Asia is projected to become the world's fastest-growing healthcare market, reaching US$5 trillion by 2030, driven by aging populations and a growing middle class [1] - The increasing demand for healthcare products and services is expected to benefit healthcare providers, health-tech innovators, and health-related infrastructure across the region [1][13] Raffles Medical Group (SGX: BSL) - Raffles Medical Group reported a revenue growth of 3.5% year-on-year to S$378.4 million for the first half of 2025 [2] - The Raffles Health Insurance segment saw a revenue increase of 10% year-on-year to S$94.9 million, while Hospital Services experienced a gain of 3.8% year-on-year to S$174 million [2] - Profits rose by 5% year-on-year to S$32.5 million, primarily driven by Hospital Services segment profits increasing by 24.3% year-on-year to S$17.7 million [3] - The company is expanding its presence in China through strategic partnerships with Shanghai Renji Hospital and Chongqing's First Affiliated Hospital [4] - RMG has a trailing price-to-earnings (PE) ratio of over 29, indicating investor optimism regarding its future growth [4][5] Abbott Laboratories (NYSE: ABTT) - Abbott Laboratories reported a 6.9% year-on-year revenue gain to US$11.4 billion for the third quarter of 2025 [6] - The diabetes care medical devices segment contributed significantly, with sales growth of 19.3% year-on-year to US$2 billion, driven by the success of the FreeStyle Libre continuous glucose monitors [7] - Abbott launched new products in India, including the FreeStyle Libre 2 Plus and AVEIR™ DR, to capture the growing demand for medical devices in Asia [8] - The company maintains a healthy dividend yield of 1.9% and a PE ratio of 16, reflecting solid fundamentals [9] ParkwayLife REIT (SGX: C2PU) - ParkwayLife REIT experienced an 8.2% year-on-year increase in gross revenue to S$117.3 million for the first nine months of 2025 [10] - Net property income rose by 8.1% year-on-year to S$110.7 million, while distribution per unit (DPU) increased by 2.3% year-on-year to S$0.1156 [10] - Growth is attributed to step-up lease agreements and acquisitions, including nursing homes in France and Japan [11] - The REIT has a healthy gearing of 35.8%, well below the regulatory limit, indicating a strong balance sheet [12] Investment Opportunities - The Asia healthcare boom represents a long-term market shift rather than a cyclical upswing, driven by increased purchasing power and an aging population [13] - The three highlighted companies tap into different aspects of the healthcare value chain, presenting early investment opportunities in resilient stocks with structural upside [14]

Group 1 - Several businesses have experienced slowdowns over the past 2 to 3 years due to prolonged high interest rates [1] - The impact of tariff implementations has become more evident, particularly affecting businesses with operations in China [1]

Group 1 - Several businesses have experienced slowdowns over the past 2 to 3 years due to prolonged high interest rates [1] - The impact of tariff implementations has become more evident, particularly affecting businesses with operations in China [1] Group 2 - The article emphasizes the importance of due diligence for investors and encourages building investment portfolios of high-quality, dividend-paying companies [2]

Core Insights - Abbott Laboratories (ABT) has received FDA approval for its Volt PFA System to treat atrial fibrillation (AFib), with plans to begin commercial cases in the U.S. and expand in the EU following earlier CE Mark approval [1][4] Company Performance - Following the FDA approval news, ABT shares dipped slightly by 0.2%, but have increased by 9.5% over the past year, outperforming the industry growth of 0.5% [2] - ABT has a market capitalization of $218.16 billion and an earnings yield of 4.1%, significantly higher than the industry's 0.1% [3] Volt PFA System Details - The Volt PFA System was approved based on the VOLT-AF IDE study involving 392 patients across multiple countries, demonstrating safety and effectiveness for both paroxysmal and persistent AFib [4][7] - The system integrates mapping, pacing, and ablation in one catheter, designed to work with Abbott's EnSite X EP System for enhanced cardiac mapping [5][7] Significance of Volt PFA System - The proprietary design of the Volt PFA System allows for efficient energy transfer to targeted tissue, aiming to reduce the need for repeat ablations and complications [6][8] - Patients can undergo the procedure with conscious sedation instead of general anesthesia, which is beneficial for those who may have barriers to anesthesia [8] Industry Context - Nearly 12 million people in the U.S. over the age of 65 have AFib, a number expected to double in the next 20 years, highlighting a growing market for effective treatment options [9] - AFib significantly increases the risk of stroke, making minimally invasive cardiac ablation procedures essential for many patients when other treatments fail [9] Additional Developments - Abbott has expanded its Lingo biowearable continuous glucose monitor system to Android devices, broadening its user base significantly [10]

Core Insights - Abbott has received FDA approval for its Volt PFA System to treat atrial fibrillation (AFib), with plans to begin commercial cases in the U.S. and expand in the EU following earlier CE Mark approval [1][2] - Approximately 12 million people in the U.S. over the age of 65 have AFib, a number expected to double in the next 20 years, highlighting the growing need for effective treatment options [1] - The Volt PFA System demonstrated strong safety and effectiveness in the VOLT-AF IDE study, which included 392 patients across multiple countries [2] Product Features - The Volt PFA System is designed to simplify AFib treatment by allowing physicians to map, pace, and ablate using a single catheter, enhancing workflow and efficiency [4][5] - Its unique balloon-in-basket design provides superior tissue contact and energy delivery, addressing limitations of earlier PFA systems [3][4] - The system allows for fewer therapy applications, which can lead to better patient outcomes and reduced risk of complications [7] Clinical Benefits - The Volt PFA System supports conscious sedation instead of general anesthesia, which can facilitate faster recovery times for patients undergoing ablation procedures [7][8] - It reduces exposure to radiation and minimizes hemolysis, making it a safer option for patients [7] - The system is clinically proven to achieve durable lesions with fewer pulses, enhancing the effectiveness of first-time procedures [6][7]

For U.S. important safety information on the Amplatzer Piccolo Occluder, visit https://abbo.tt/PiccoloISI. For U.S. Important Safety Information about the Masters HP 15mm valve, visit https://abbo.tt/MastersISI. "We designed the Amplatzer Piccolo Delivery System based on feedback from leading physicians across the world to make PDA closure procedures even safer and easier," said Sandra Lesenfants, senior vice president of Abbott's structural heart business. "With the Amplatzer Piccolo Occluder, which is the ...